NRx Pharmaceuticals announced the pricing of its underwritten public offering of shares at a public offering price of $3.30 per share, for aggregate gross proceeds of approximately $2M. The offering is expected to close on April 19. EF Hutton is acting as the sole book-runner for the offering. NRx is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- NRx Pharmaceuticals announces new data on NRX-101
- NRx Pharmaceuticals develops new proprietary formulation of HTX-100
- NRx Pharmaceuticals achieves data-lock of Phase 2b/3 trial of NRX-101
- NRX Pharmaceuticals trading halted, news pending
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
